Novel Methylated DNA Markers Discriminate Advanced Neoplasia in Pancreatic Cysts: Marker Discovery, Tissue Validation, and Cyst Fluid Testing

Shounak Majumder, William R. Taylor, Tracy C. Yab, Calise K. Berger, Brian A. Dukek, Xiaoming Cao, Patrick H. Foote, Chung Wah Wu, Douglas W. Mahoney, Harry R. Aslanian, Carlos Fernández-Del Castillo, Leona A. Doyle, James J. Farrell, William E. Fisher, Linda S. Lee, Yvonne N. Lee, Walter Park, Clifton Rodrigues, Bonnie Elyssa Gould Rothberg, Ronald R. SalemDiane M. Simeone, Sumithra Urs, George Van Buren, Thomas Christopher Smyrk, Hatim T. Allawi, Graham P. Lidgard, Massimo Raimondo, Suresh T. Chari, Michael L. Kendrick, John B. Kisiel, Mark D. Topazian, David A. Ahlquist

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

OBJECTIVES:Pancreatic cystic lesions (PCLs) may be precancerous. Those likely to harbor high-grade dysplasia (HGD) or pancreatic cancer (PC) are targets for surgical resection. Current algorithms to predict advanced neoplasia (HGD/PC) in PCLs lack diagnostic accuracy. In pancreatic tissue and cyst fluid (CF) from PCLs, we sought to identify and validate novel methylated DNA markers (MDMs) that discriminate HGD/PC from low-grade dysplasia (LGD) or no dysplasia (ND).METHODS:From an unbiased whole-methylome discovery approach using predefined selection criteria followed by multistep validation on case (HGD or PC) and control (ND or LGD) tissues, we identified discriminant MDMs. Top candidate MDMs were then assayed by quantitative methylation-specific polymerase chain reaction on archival CF from surgically resected PCLs.RESULTS:Of 25 discriminant MDMs identified in tissue, 13 were selected for validation in 134 CF samples (21 cases [8 HGD, 13 PC], 113 controls [45 ND, 68 LGD]). A tree-based algorithm using 2 CF-MDMs (TBX15, BMP3) achieved sensitivity and specificity above 90%. Discrimination was significantly better by this CF-MDM panel than by mutant KRAS or carcinoembryonic antigen, with areas under the receiver operating characteristic curve of 0.93 (95% confidence interval: 0.86-0.99), 0.71 (0.57-0.85), and 0.72 (0.60-0.84), respectively. Cutoffs for the MDM panel applied to an independent CF validation set (31 cases, 56 controls) yielded similarly high discrimination, areas under the receiver operating characteristic curve = 0.86 (95% confidence interval: 0.77-0.94, P = 0.2).DISCUSSION:Novel MDMs discovered and validated in tissue accurately identify PCLs harboring HGD/PC. A panel of 2 MDMs assayed in CF yielded results with potential to enhance current risk prediction algorithms. Prospective studies are indicated to optimize and further evaluate CF-MDMs for clinical use.

Original languageEnglish (US)
Pages (from-to)1539-1549
Number of pages11
JournalAmerican Journal of Gastroenterology
Volume114
Issue number9
DOIs
StatePublished - Sep 1 2019

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Novel Methylated DNA Markers Discriminate Advanced Neoplasia in Pancreatic Cysts: Marker Discovery, Tissue Validation, and Cyst Fluid Testing'. Together they form a unique fingerprint.

  • Cite this

    Majumder, S., Taylor, W. R., Yab, T. C., Berger, C. K., Dukek, B. A., Cao, X., Foote, P. H., Wu, C. W., Mahoney, D. W., Aslanian, H. R., Fernández-Del Castillo, C., Doyle, L. A., Farrell, J. J., Fisher, W. E., Lee, L. S., Lee, Y. N., Park, W., Rodrigues, C., Gould Rothberg, B. E., ... Ahlquist, D. A. (2019). Novel Methylated DNA Markers Discriminate Advanced Neoplasia in Pancreatic Cysts: Marker Discovery, Tissue Validation, and Cyst Fluid Testing. American Journal of Gastroenterology, 114(9), 1539-1549. https://doi.org/10.14309/ajg.0000000000000284